Obligation to notify placing on the market etcU.K.
73.—(1) The holder of a UK marketing authorisation must notify the licensing authority of the date on which the product to which the authorisation relates is placed on the market in the United Kingdom, taking account of the various presentations authorised.
(2) A notification under paragraph (1) must be given before the end of the period of two months beginning with the date on which the product is placed on the market.
(3) The holder of a UK marketing authorisation must notify the licensing authority if the product to which the authorisation relates is to be withdrawn from the market in the United Kingdom (whether temporarily or permanently).
(4) A notification under paragraph (3) must be given before the beginning of the period of two months ending with the date on which the product is to be withdrawn from the market unless it is not reasonably practicable to do so.
(5) In that event, the notification must be given as far as is reasonably practicable in advance of the date on which the product is withdrawn from the market.
[F1(5A) The holder of a UK marketing authorisation must notify the licensing authority forthwith if the holder takes action to—
(a)request the cancellation of the authorisation;
(b)not apply for the renewal of the authorisation; or
(c)withdraw the product to which the authorisation relates from the market in a [F2country other than the United Kingdom] (whether temporarily or permanently) and the action is based on any of the grounds set out in Article 116 or 117(1) of the 2001 Directive.
(5B) A notification under paragraph (3) or (5A) must include the reasons for the action, in particular declaring if the action is based on any of the grounds set out in Article 116 or 117(1) of the 2001 Directive.
(5C) The holder of a [F3UKMA(NI) or UKMA(UK)] must also notify the EMA forthwith where the action which is the subject of a notification by the holder under paragraph (3) or (5A) is based on any of the grounds set out in Article 116 or 117(1) of the 2001 Directive.]
(6) The licensing authority may require the holder of a UK marketing authorisation to provide—
(a)information relating to the volume of sales in the United Kingdom of the product to which the authorisation relates; or
(b)information of which the holder is aware relating to the volume of prescriptions in the United Kingdom for the product.
(7) The holder of a UK marketing authorisation must provide the licensing authority with information that it requires under paragraph (6)—
(a)where the period within which the information must be provided is specified in a written notice given to the holder by the licensing authority, before the end of that period; or
(b)otherwise, as soon as is reasonably practicable after receipt of the request.
Textual Amendments
F1Reg. 73(5A)-(5C) inserted (11.11.2013) by The Human Medicines (Amendment) (No. 2) Regulations 2013 (S.I. 2013/2593), regs. 1(2), 3
F2Words in reg. 73(5A)(c) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 82(2); 2020 c. 1, Sch. 5 para. 1(1)
F3Words in reg. 73(5C) substituted (31.12.2020) by virtue of S.I. 2019/775, reg. 82(3) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 60)